{"id":2563,"date":"2016-06-22T06:49:54","date_gmt":"2016-06-22T10:49:54","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=2563"},"modified":"2016-06-23T08:29:43","modified_gmt":"2016-06-23T12:29:43","slug":"progress-report-new-antibacterials-in-the-fight-against-mdr-bacteria","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2016\/06\/22\/2563\/progress-report-new-antibacterials-in-the-fight-against-mdr-bacteria\/","title":{"rendered":"Progress Report: New Antibacterials In the Fight against MDR Bacteria"},"content":{"rendered":"

\"Pipeline<\/a><\/p>\n

Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the \u2018Guideline Wars\u2019, i.e., those never ending discussions about regulatory requirements, have contributed to this trend in a major way as well.<\/p>\n

First, we had a decade of regulatory uncertainty. The 1998 Guidelines, still hot off the press, all of a sudden were no longer relevant and replaced by\u00a0\u2018new science criteria\u2019 used by but not communicated by FDA. Many late-phase projects became\u00a0stranded.<\/p>\n

The reaction of Big Pharma came swiftly. Even companies traditionally active in antibiotic research were uncertain how to develop a new antibiotic with a reasonable chance of success. FDA started to talk about PROs, new endpoints (the \u201cfeel-function-survive\u201d mantra), placebo-controls, dose-finding and superiority trials, no-prior-antibiotics criteria, new endpoints and untested time points, and the need for clinical justification of\u00a0non-inferiority\u00a0margins. All these issues were brought up at the same time creating a cacophony of voices pro and con.\u00a0 While many stakeholder were involved, in the end regulators chose to listen more to their statisticians than to clinicians. At the end of the decade we still did not have new guidelines that were practical.<\/p>\n

By then Roche, Bayer, Novartis, Pfizer, AstraZeneca, BMS, Johnson & Johnson, GSK and many other big pharmas had found greener pastures: if they stayed in anti-infectives, they concentrated their activities on HIV and HCV. But most chose to leave the field in order to pan for gold somewhere else: in oncology. While in the 90ies every company worth its metal had a fluroquinolone under development, 10 years later every large pharma was developing a tyrosine kinase inhibitor. It simply made no sense for them to deal with MDR pathogens and a regulatory world in constant flux which no longer followed ICH guidelines and promised nothing but blood, sweat and tears \u2013 i.e., low revenue potential, shifting guidelines. and an uncertain approval path.<\/p>\n

Besides economic and political\/regulatory factors, there were other\u00a0disincentives as well. It became painfully clear to drug developers that the era of broad-spectrum antibiotics was over. Narrow spectrum agents were still around\u00a0and developed by idealistic VCs, but such compounds promised a smaller ROI than Big Pharma wanted for their investments. And those investment costs had risen rapidly over the years.<\/p>\n

While all this happened resistance continued to march on. A perfect storm was in the making.<\/p>\n

It took an act of Congress to force the FDA\u2019s hand to issue new guidelines for drug developers, and FDA eventually complied. The new Guidances released by FDA in installments from 2010 onwards were lengthy documents, totally impractical for clinical implementation but rich in do\u2019s and don\u2019ts. It proved hard to find these idealized patients that met the new enrollment criteria. For those working in the area, this was yet another bag of disincentives, bundled up in a cover of pseudoscience, and wrapped in gift paper. Industry was not fooled and stayed on the sidelines. The European Medicines Agency chose not to follow FDA\u2019s new rule book.<\/p>\n

IDSA and some other stakeholders saw a need to step in. In 2010 the 10 by \u201920 Initiative was created in the hopes of rekindling antibiotic research, focusing on areas of high need. In Europe, the IMI initiative had a similar goal fostering collaboration in private\/public partnerships.<\/p>\n

Where are we now, 5\u00bd years later? \u00a0A recent publications [1] sums up the new antibiotics that made it to the market so far:\"New<\/a><\/p>\n

In this list of 8 new drugs, 2 stand out as being different: Fidaxomicin, a non-systemic drug for C. difficile infection, developed without the benefit of an FDA Guidance, and bedaquiline, a drug for MDR TB with a development path entirely different from other antibacterials. Both drugs are significant newcomers and welcome additions to our armamentarium.<\/p>\n

This leaves us with 6 systemically active new antibacterials approved in the last 5 years of which at least 2 squarely meet the high-need criteria established by IDSA: Ceftolozane\/tazobactam and Ceftazidime\/avibactam. Both drugs work against ESKAPE pathogens, both have excellent activity against Pseudomonas aeruginosa, both have activity against ESBLs and\/or CRE pathogens. Both are bactericidal drugs and potentially life-saving. At a time when so many hospitalized patients require\u00a0a penem or end up on colistin for lack of an alternative, both drugs will certainly play a significant role in MDR infections.<\/p>\n

The other drugs on the list are not just me-too\u2019s. Dalbavancin and oritavancin have significantly prolonged half-lives; it\u00a0differentiates them from vancomycin as it did\u00a0ceftriaxone from other\u00a03rd<\/sup> generation cephalosporins. The MRSA activity of ceftaroline is an important new feature for the class. Tedizolid may well have a better long-term safety profile than linezolid, a feature which will require longer-term Phase 4 trials to prove definitively. Remember, it is unrealistic to expect a full characterization of all drug properties in a registration program, and long-term\u00a0safety studies are not done\u00a0prior to registration. In summary, while the list is short, is has brought us some truly excellent drugs that address major clinical needs.<\/p>\n

Deak et al. [1] have a more cynical perspective.<\/p>\n

According to them, none of these new drugs demonstrated \u2018evidence of additional benefit\u2019. This is an almost laughable conclusion which can be refuted along several lines of evidence. For one, why then did FDA fast-track these drugs, give them priority review, or QIDP status?\u00a0 In the table column headed \u201cIn-vitro activity against ESKAPE pathogens\u201d the authors themselves list 2 new drugs as meeting this criterium.<\/p>\n

Similarly, we also disagree with the authors when they\u00a0state that the new drugs do not represent \u2018biological innovation\u2019 or lack \u2018public health importance\u2019. Just the contrary.<\/p>\n

The authors further complain that MDR-specific microbiological benefits were not proven. Sorry guys, but in a traditional Phase 3 trial program this simply is not feasible. Has any of these expert authors who seem to have no personal experience in clinical development, ever talked to someone who actually has worked in clinical development? Clearly, these drugs would have shown superiority against MDR pathogens if we could test them head-to-head against another antibiotic devoid of MDR activity and in a patient population of only MDR infections. However, such studies are not ethical and our diagnostics are not sophisticated enough and do not help us select MDR patients a-priori.<\/p>\n

While proving superiority is easy in hypertension trials, it is next to impossible in antibacterial drug development. It is for that exact reason that current FDA Guidances mainly discuss non-inferiority trial designs.<\/p>\n

The authors go on to thank FDA for speedy fast-track reviews \u2013 instead we\u00a0would like to thank the small and mid-size companies that continued antibiotic development at a time of regulatory confusion and corporate realignment. We see no reason to thank FDA for\u00a0effectively shutting down the anti-infective development effort in Big Pharma in the quixotical pursuit of ‘perfection’.<\/p>\n

While we agree with the facts presented in the article, we disagree strongly with the conclusions. By ignoring the bigger picture the authors present a very narrow view which appears self-serving and ideological. Nobody can be happy with the status quo, for sure. We are not glossing over the fact that the pipeline is disappointingly empty, we know that already.\u00a0 But it is important to understand where we came from, and why we are where we are.<\/p>\n

 <\/p>\n

Reference:
\n<\/strong>[1] D Deak. Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of U.S. Food and Drug Administration\u2013Approved Antibiotics, 2010 \u20132015. Ann Int Med May 2016; doi:10.7326\/M16-0291<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the \u2018Guideline Wars\u2019, i.e., those never ending discussions about regulatory requirements, have contributed to this trend in a Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":2588,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[553,81,1469,1682,403,1515,585,353,974,220,1516,1359,796,783,828,288,344,354,177,363,229,355,66,85,228,89,597,625,350,240,1679,362,5,99,88,246,1583,27,1678,1163,204,1680,83,158,1677,1681,234,67,197,882,754,655,881,1371,184,801,1518,462,180,7,829,480,404,48,1470],"class_list":["post-2563","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-10-x-20-initiative","tag-absssi","tag-allergan","tag-antibiotic-approvals","tag-antibiotic-blog","tag-antibiotic-pipeline","tag-astrazeneca","tag-avibactam","tag-avycaz","tag-bayer","tag-bedaquiline","tag-bli","tag-bms","tag-cabp","tag-ceftaroline","tag-ceftazidimeavibactam","tag-ceftolozanetazobactam","tag-ciai","tag-colistin","tag-cre","tag-cubicin","tag-cuti","tag-dalbavancin","tag-dalvance","tag-daptomycin","tag-dificid","tag-durata","tag-ema","tag-esbl","tag-eskape","tag-expedited-review","tag-fast-track","tag-fda","tag-fda-guidance","tag-fidaxomicin","tag-gsk","tag-harald-reinhart","tag-idsa","tag-imi","tag-johnson-johnson","tag-mdr-pathogens","tag-mdr-tb","tag-mrsa","tag-non-inferiority-margins","tag-novel-antibiotics","tag-novexel","tag-orbactiv","tag-oritavancin","tag-p-aeruginosa","tag-patient-reported-outcomes","tag-penem","tag-pfizer","tag-pro","tag-qidp","tag-roche","tag-sanofi","tag-sirturo","tag-sivextro","tag-tazobactam","tag-tedizolid","tag-teflaro","tag-the-medicines-company","tag-tuberculosis","tag-vancomycin","tag-zinforo"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/06\/Pipeline-slider.jpg?fit=638%2C179&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-Fl","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":1408,"url":"https:\/\/allphasepharma.com\/dir\/2015\/05\/07\/1408\/no-such-thing-as-a-free-ride\/","url_meta":{"origin":2563,"position":0},"title":"No Such Thing as a Free Ride\u2026","author":"Harald","date":"May 7, 2015","format":false,"excerpt":"..when it comes to FDA review of antibiotic NDAs.\u00a0 Some seem to have forgotten the dismal record of antibiotic approvals in the last 15 years, and the long list of failed submissions.\u00a0 Many failed not because of lack of efficacy or a bad safety profile but because of changes in\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"theBMJ","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/05\/theBMJ.jpg?resize=350%2C200","width":350,"height":200},"classes":[]},{"id":2289,"url":"https:\/\/allphasepharma.com\/dir\/2016\/02\/10\/2289\/the-10-x-20-goal-are-we-on-track\/","url_meta":{"origin":2563,"position":1},"title":"The 10 x \u201920 Goal \u2013 Are We On Track?","author":"Harald","date":"February 10, 2016","format":false,"excerpt":"In the last decade (2000-2010), we saw the number of new antibiotic approvals drop successively each year; FDA changed the rules of the approval process without providing public guidance; many antibiotic companies fled the therapeutic area; investments were redirected to oncology projects which had a much better ROI. The IDSA\u2026","rel":"","context":"In "The News"","block_context":{"text":"The News","link":"https:\/\/allphasepharma.com\/dir\/category\/the_news\/"},"img":{"alt_text":"10x20 blog - slider copy","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/10x20-blog-slider-copy.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/10x20-blog-slider-copy.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/10x20-blog-slider-copy.jpg?resize=525%2C300 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/10x20-blog-slider-copy.jpg?resize=700%2C400 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/02\/10x20-blog-slider-copy.jpg?resize=1050%2C600 3x"},"classes":[]},{"id":1887,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/26\/1887\/avicaz-approval-and-labeling-restrictions\/","url_meta":{"origin":2563,"position":2},"title":"Avycaz Approval and Labeling Restrictions","author":"Harald","date":"August 26, 2015","format":false,"excerpt":"On Feb 25, 2015 the combination of ceftazidime\/avibactam (Avycaz) was approved by FDA for cUTI and cIAI infections in\u00a0patients \u2018who have limited or no alternative treatment options\u2019.\u00a0 As a QIDP drug, Avycaz\u00a0received priority review.\u00a0 Its label states that it is indicated for infections caused by pathogens proven or \u2018suspected to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Avycaz - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/Avycaz-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/Avycaz-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/Avycaz-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":5040,"url":"https:\/\/allphasepharma.com\/dir\/2025\/08\/21\/5040\/an-intro-to-emblaveo-aztreonam-avibactam\/","url_meta":{"origin":2563,"position":3},"title":"An Intro to Emblaveo (aztreonam + avibactam)","author":"Harald","date":"August 21, 2025","format":false,"excerpt":"The FDA web site usually provides label and review documents for approved drugs.[1]\u00a0 Emblaveo, the combination of aztreonam and avibactam, was approved in February 2025, almost \u00bd year ago, but clinical review documents are still not posted at the site.[2]\u00a0 Hence, we do not know how Regulators felt about the\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/avibactam-Stick-Model.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/avibactam-Stick-Model.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/avibactam-Stick-Model.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/avibactam-Stick-Model.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/avibactam-Stick-Model.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/avibactam-Stick-Model.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":2817,"url":"https:\/\/allphasepharma.com\/dir\/2016\/10\/24\/2817\/qidp-drug-update-part-2-categories-of-interest\/","url_meta":{"origin":2563,"position":4},"title":"QIDP Drug Update \u2013 Part 2: \u00a0Categories of Interest","author":"Harald","date":"October 24, 2016","format":false,"excerpt":"According to Janet Woodcock, 63 drugs have been given the \u201cQIDP\u201d designation so far. Our inofficial list has 61 drugs, of which we believe only 57 are still in active clinical development.\u00a0 So we are in fairly close agreement. That may seem like an impressive record but it is also\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"qidp-part2-slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2016\/10\/QIDP-Part2-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":5099,"url":"https:\/\/allphasepharma.com\/dir\/2025\/08\/23\/5099\/emblaveo-aztreonamavibactam-microbiology-testing-for-mdr-pathogens\/","url_meta":{"origin":2563,"position":5},"title":"EMBLAVEO (AZTREONAM+AVIBACTAM) Microbiology Testing for MDR Pathogens","author":"Harald","date":"August 23, 2025","format":false,"excerpt":"The discussion emphasizes challenges in clinical antibiotic trials which failed to effectively target multi-drug resistant (MDR) pathogens. It advocates for using rapid PCR diagnostics to streamline trials, ensuring focus on pathogens of concern, and calls for regulatory adaptations to enhance study design and antibiotic testing efficacy.","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/image-13.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/image-13.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/image-13.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2025\/08\/image-13.png?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=2563"}],"version-history":[{"count":16,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2563\/revisions"}],"predecessor-version":[{"id":2589,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/2563\/revisions\/2589"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/2588"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=2563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=2563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=2563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}